- Home
- SBET vs XERS Comparison
SBET vs XERS Comparison
Compare SBET & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | XERS |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBET | XERS |
|---|---|---|
| Price | $8.57 | $8.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $18.71 | $10.83 |
| AVG Volume (30 Days) | ★ 8.1M | 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | $28,055,000.00 | ★ $49,590,000.00 |
| Revenue This Year | $105.19 | $34.37 |
| Revenue Next Year | $13.53 | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | 142.67 |
| 52 Week Low | $4.46 | $5.25 |
| 52 Week High | $19.53 | $10.08 |
Technical Indicators
Market Signals| Indicator | SBET | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 68.60 | 50.16 |
| Support Level | $6.05 | $8.00 |
| Resistance Level | $10.91 | $9.01 |
| Average True Range (ATR) | 0.45 | 0.30 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 82.37 | 24.20 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.